Format

Send to

Choose Destination
J Neuropsychiatry Clin Neurosci. 1999 Winter;11(1):79-85.

Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque.

Author information

1
U.S. Department of Veterans Affairs Sepulveda Medical Centers, Los Angeles, California, USA. jfitten@ucla.edu

Abstract

The cholinesterase inhibitor tacrine (THA) and the M1 muscarinic agonist AF102B (cevimeline), both reported to enhance cognition in animals and humans, were tested in 5 macaques for reduction of spontaneous, random movements. Monkeys were videotaped 1 hour after administration of normal saline vehicle, after low- and high-dose intramuscular AF102B, and after low- and high-dose oral THA. Two independent blind judges counted numbers of spontaneous movements made by each monkey over 12 consecutive 15-second segments for each drug condition. Both THA and AF102B reduced movement significantly at high doses without overt side effects, warranting further research on the agitation-reducing potential of cognition-enhancing cholinomimetic drugs.

PMID:
9990560
DOI:
10.1176/jnp.11.1.79
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center